

REMARKS/ARGUMENTS

Claims 1-19 are replaced by new claims 20-22. The new claims are supported by the specification, for example at original claim 10, page 11, fourth full paragraph, and page 38, fifth full paragraph.

Applicants submit that the new claims overcome the reasons that the claims were rejected under 35 USC 112, second paragraph. Therefore, withdrawal of this rejection is requested.

Claims 10-18 were rejected under 35 USC 103(a) over Wood et al and Remiszewski et al. Applicants request reconsideration and withdrawal of this rejection for the reasons that follow.

Attached is a copy of Qian et al, Cancer Research 64, 6626-6634 (September 15, 2004), which is not prior art to this application based on the claim of priority to Provisional Application No. 60/505250, filed September 23, 2003. Quan et al describes experiments wherein the combination of a VEGF inhibitor, PTK787, and an histone deacetylase inhibitor, LAQ824, show a greater *in vivo* antitumor effect compared with single agents and a synergistic effect in isobologram A on page 6630. Applicants assert that the experiments described in Qian et al demonstrate the patentability of the presently claimed invention.

Applicants request withdrawal of the rejection under 35 USC 103(a) for the reasons discussed above.

Entry of this amendment and reconsideration and allowance of the claims are respectfully requested.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Respectfully submitted,



---

George Dohmann  
Attorney for Applicant  
Reg. No. 33,593

Date: 10/20/09

Enc.: Qian et al, Cancer Research 64, 6626-6634 (September 15, 2004)